What is happening between IFM Investors and Atlas Arteria (ASX:ALX)?

IFM Investors has launched a $7 billion hostile takeover bid for toll road operator Atlas Arteria. The situation escalated after Atlas Arteria's board formally rejected IFM’s $4.75-per-share cash offer, prompting IFM to publicly slam the target company's independent valuation report.

Why did the Atlas Arteria (ASX:ALX) board reject the takeover bid?

The board rejected the $4.75-per-share bid because it considers the price too low, opportunistic, and highly conditional. Their rejection is backed by an independent expert report from Kroll, which valued the company's control range much higher, between $5.39 and $6.20 per share.

How has IFM Investors responded to the independent expert valuation of Atlas Arteria?

IFM Investors hit back by filing a supplementary bidder's statement that calls Kroll’s independent expert report unbalanced, selective, and misleading. IFM claims the valuation framework relies on multiple omissions and unreasonable assumptions to artificially inflate Atlas Arteria's worth.

What leverage does IFM Investors hold over Atlas Arteria (ASX:ALX)?

IFM Investors already owns a powerful 35% blocking stake in Atlas Arteria. This massive pre-existing position makes it incredibly difficult for any rival suitors to emerge or for Atlas Arteria management to pass major structural changes without IFM's approval.

Will IFM Investors increase its $4.75 cash offer for Atlas Arteria (ASX:ALX)?

IFM has explicitly stated that its $4.75-per-share cash offer is its "best and final" consideration, meaning they do not intend to raise the price. However, they left a standard legal loophole: the price will only stay fixed "in the absence of a competing proposal".

Image for illustrative purposes only. Not a real photo.

IFM slams Atlas Arteria over "misleading" valuation

Written by Brie CarterPublished Jun. 1 2026Last Updated Jun. 1 2026

IFM Investors has launched a blistering counter-attack against its takeover target, toll road operator Atlas Arteria (ASX:ALX), branding an independent expert report used to block its $7 billion hostile bid as "unbalanced, selective, and misleading".

The escalations follow a formal target's statement issued last week, in which the Atlas Arteria board rejected IFM’s $4.75-per-share cash offer, characterising the approach as "too low, opportunistic, and highly conditional".

That rejection relied heavily on a valuation from independent expert Kroll, which assessed the company’s fair control value higher, between $5.39 and $6.20 per share.

However, in a third supplementary bidder’s statement lodged early Monday morning, IFM—which already commands a powerful 35% blocking stake in the toll road giant—hit back aggressively.

The infrastructure specialist claimed Kroll’s valuation framework was compromised by "a number of omissions and unreasonable assumptions".

IFM took direct aim at the board's defence strategy, dismissing claims that Atlas Arteria could unlock superior value for shareholders independently through strategic asset sales or new operational initiatives as "not credible".

IFM cautioned investors that its patience is limited, warning that the current proposal represents a rare window for certain liquidity.

"The offer represents a limited opportunity to realise cash-certain value," IFM stated, emphasising that its maximum consideration is now "best and final" unless a rival suitor emerges.

At the time of reporting, Atlas Arteria’s share price was $5.02.